Roche’s Alecensa Gets FDA Green Light; ImmunityBio Gains as PDUFA Date Approaches for Bladder Cancer Drug; Key Drug Trial Failures in 2024 New York, N.Y., April 22, 2024 - PRISM MarketView - Healthcare equities finished mostly higher after a very quiet trading session on Friday. The S&P 500 Healthcare Index closed up +0.32% versus the S&P 500 Index which lost (0.88%) and the XBI settled down (0.78%). A lack of momentum today left Roche stock up by just +0.95% following the FDA greenlit...

PRISM Market Pulse: Market Tumbles Amid Fed's Rate Stance; Mixed Corporate Earnings Highlight Sector Struggles New York, N.Y., April 19, 2024 - PRISM MarketView - Equities were down in the morning and into midday as the major indices remain on track to notch their third straight week of declines. Fedspeak continues to support the “higher-for-longer” narrative with no urgency to cut rates which has created further sharp outflows and investor skepticism. The Street has taken investors’ pulses in...

New York, N.Y., April 18, 2024 - PRISM MarketView - More than 83,000 new cases of bladder cancer are diagnosed in the US each year, and the illness is responsible for around 17,000 deaths annually. Urothelial carcinoma accounts for 90% of bladder cancers in the US and western Europe, and surgery, followed by chemotherapy or radiation is the current standard of care. There are 24 drugs approved by the FDA for bladder cancer, but due to invasive and life-changing surgical procedures, researchers...

Mobile-Health Network Solutions (MNDR) IPOs; Q32 Bio Surges; EMA Concludes GLP-1 Drugs Not Associated with Suicidal Thoughts New York, N.Y., April 15, 2024 - PRISM MarketView - Healthcare equities finished lower on Friday, in line with broad declines across the market. The S&P 500 Healthcare Index closed down (1.52%) versus the S&P 500 Index which lost (1.46%) and the XBI settled down (3.43%). The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee concluded...

New York, N.Y., March 25, 2024 - PRISM MarketView - Drug development is an arduous, costly and time-consuming process for the teams involved behind the scenes, and the patients anxiously awaiting breakthroughs in different disease areas. It takes 12 years on average for a company to take a drug from discovery to commercialization, and every hard-won FDA approval is a cause for celebration for researchers, companies and the end-users whose lives may be changed by these treatments. The past few...

New York, N.Y., March 18, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™ and the companies leading the charge in developing new, safe, and effective treatments for liver disease. The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease, a leading cause of liver-related mortality that affects between...